A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

40 sites for NCT04765059

EGFR Mutation

Non-Squamous Non-Small Cell Lung Carcinoma

carboplatin, +3 more drugs

chemotherapy, +1 more type

Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

61 sites for NCT03318939

EGFR A763_Y764insFQEA, +31 more biomarkers

Non-Small Cell Lung Carcinoma

poziotinib

targeted therapy

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

81 sites for NCT02609776

EGFR A763_Y764insFQEA, +19 more biomarkers

Lung Adenocarcinoma, +2 more conditions

amivantamab, +3 more drugs

chemotherapy, +1 more type

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

71 sites for NCT04077463

EGFR Mutation

Non-Small Cell Lung Carcinoma

amivantamab, +3 more drugs

chemotherapy, +1 more type

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

1 site for NCT04958811

EGFR Mutation, +2 more biomarkers

Non-Squamous Non-Small Cell Lung Carcinoma

atezolizumab, +2 more drugs

immunotherapy, +1 more type

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

10 sites for NCT04413201

EGFR Mutation

Non-Squamous Non-Small Cell Lung Carcinoma

afatinib, +2 more drugs

targeted therapy

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

2 sites for NCT05176665

EGFR Amplification, +7 more biomarkers

Cholangiocarcinoma, +2 more conditions

EMB-01

targeted therapy

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

2 sites for NCT05163028

EGFR Mutation, +1 more biomarker

Malignant Solid Tumor

HBI-2376

targeted therapy

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

35 sites for NCT04591431

AKT1 Amplification, +59 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +19 more drugs

immunotherapy, +1 more type

Biomarker-based Study in R/M SCCHN

30 sites for NCT03088059

CCND1 Amplification, +11 more biomarkers

Hypopharyngeal Squamous Cell Carcinoma, +4 more conditions

afatinib, +6 more drugs

immunotherapy, +1 more type

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

29 sites for NCT04140526

ALK Fusion, +6 more biomarkers

Breast Carcinoma, +3 more conditions

ONC-392, +2 more drugs

immunotherapy, +1 more type

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

2 sites for NCT05068024

EGFR Exon 20 Insertion, +1 more biomarker

Non-Small Cell Lung Carcinoma

FWD1509 MsOH

targeted therapy